GlassScriptPhysician profile
Nanfu Deng
NPI 1396241196
$3,546.95
in general payments reported to CMS, 2019-2025
26 companies · $937 in 2025
The $937 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $315 · 2022: $937 · 2023: $792 · 2024: $566 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $842.99 | 2021-2023 | Resolution Clip, Acquire, Wallflex Duodenal |
| Abbvie INC. | $598.86 | 2022-2025 | Creon, Linzess |
| Conmed Corporation | $363.39 | 2023-2025 | Conmed Generators, Conmed Biliary |
| Genzyme Corporation | $245.31 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $193.85 | 2024-2025 | Zenpep |
| Steris Corporation | $167.00 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.15 | 2024-2025 | Xifaxan |
| Medtronic, INC. | $148.60 | 2022 | |
| Janssen Biotech, INC. | $126.58 | 2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $123.90 | 2024 | Stelara, Tremfya, Remicade |
| Intercept Pharmaceuticals, INC. | $119.13 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.97 | 2023-2024 | Gattex, Entyvio |
| Sanofi-Aventis U.S. LLC | $48.19 | 2024-2025 | |
| 3-D Matrix, INC. | $41.27 | 2024 | |
| Radius Health, INC. | $37.49 | 2024 | Tymlos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $34.22 | 2022 | |
| Ibsa Pharma INC. | $29.94 | 2025 | Licart, Tirosint, Flector |
| Tandem Diabetes Care, INC. | $28.39 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $18.62 | 2025 | Omnipod |
| Dynavax Technologies Corporation | $18.22 | 2025 | Heplisav-B |
| Lilly USA, LLC | $16.40 | 2025 | Kisunla |
| Xeris Pharmaceuticals, INC. | $16.34 | 2025 | Keveyis |
| Merck Sharp & Dohme LLC | $15.95 | 2025 | Gardasil 9, Capvaxive |
| Abbott Laboratories | $15.88 | 2025 | Freestyle Libre 3 |
| Evoke Pharma, INC. | $15.63 | 2025 | |
| Amgen INC. | $14.68 | 2025 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanfu Deng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.